Oncología

Actualizaciones de Congresos

Notas de prensa, eventos y entrevistas
asco 2023

2023

Larotrectinib Pacientes Adultos

ASCO, Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer. (Hong DS, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 3141).

Larotrectinib Pacientes con Cáncer de Pulmón

ASCO, Long-term efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. (Lin JJ, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 9056).

Larotrectinib en Pacientes con Cáncer de Tiroides

ASCO, Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC). (Cabanillas ME, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 6091).

esmo 2023

2023

Larotrectinib Extended data set

ESMO, Larotrectinib Extended Data Set (A. Drilon, et al, Annals of Oncology, Volume 34, Suplement 2, 2023, Page S470.

Larotrectinib en primera línea

ESMO, Efficacy and safety of Larotrectinib as first-line treatment for patients with TRK fusion cancer (Hong DS, et al, Annals of Oncology, Volume 34, Suplement 2, 2023, Page S469.

ctso 2023

2023

Larotrectinib en pacientes adultos con sarcomas

CTOS, Updated efficacy and safety of Larotrectinib in adult patients with TRK fusion sarcomas (McDermott R, et al. Poster presentation at CTOS 2023:Abstract 1569432).

Efficacy, safety, and treatment hold wait-and-see outcomes of Larotrectinib in pediatric patients

CTOS, Efficacy, safety, and treatment hold wait-and-see outcomes of Larotrectinib in pediatric patients with TRK fusion sarcomas (Albert CM, et al. Poster presentation at CTOS 2023:Abstract 1570241).

siop 2023

2023

Larotrectinib Historical Comparison Orbach

SIOP, Comparison of clinical outcomes of patients with infantile fibrosarcoma treated with Larotrectinib in the SCOUT study versus historical cohort THE EPI-VITRAKVI STUDY (D. Orbach, et al.44O. ESMO Open, Volume 8, Issue 1, Supplement 3, 2023).

SNO 2023

2023

Larotrectinib Data SNO

SNO, Efficacy and safety of Larotrectinib in patients with TRK fusion primary central nervous system tumors: An updated analysis (Perreault S, et al. Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v95). 

asco 2024

2024

Larotrectinib in GI Cancer

ASCO, Updated efficacy and safety of Larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer (Lin Shen et al., Updated efficacy and safety of Larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.. JCO 42, 109-109(2024)). DOI: